Using Tranexamic Acid to Treat Skin Pigmentation Disorders
Official title: The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans
Run by Henry Ford Health System · NCT04233749 · Data updated 2026-11-12
This study is testing if tranexamic acid can help people with skin pigmentation disorders like lichen planus pigmentosus and erythema dyschromicum perstans feel better and improve their skin color.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5 (estimated) |
| Sponsor | Henry Ford Health System Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Status | Recruiting |
| Started | March 17, 2020 |
| Main results expected | December 30, 2025 |
| Study ends | December 30, 2025 |
| Registry record updated | September 9, 2025 |
| Trial ID | NCT04233749 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with LPP, EDP, or ashy dermatosis.
✕Probably not a fit
Patients with a history of clotting disorders, active malignancies, or severe renal impairment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the efficacy of tranexamic acid in treating lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP), two challenging pigmentary disorders. The study aims to determine if tranexamic acid, known for its ability to reduce pigmentation in melasma, can similarly benefit patients with LPP and EDP. Participants will receive tranexamic acid tablets after a washout period from other treatments. The trial will assess changes in pigmentation and overall skin condition in affected individuals.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients suffering from LPP and EDP, improving their skin appearance and quality of life.
How similar studies have gone: While tranexamic acid has shown promise in treating melasma, its application for LPP and EDP is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject age 18 and older * Subject with a diagnosis of LPP, EDP, or AD * Subject able to understand requirements of the study and risks involved * Subject able to sign a consent form * Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment Exclusion Criteria: * Personal history of clotting disorder or thromboembolic disease (deep vein thrombosis (DVT), stroke, etc) * Active malignancy, excluding non-melanoma skin cancer * Moderate to severe renal impairment * History of migraine with aura * Current anticoagulant therapy * Current use of hormonal contraception or hormone replacement therapy in the last 30 days * A woman who is lactating, pregnant, or planning to become pregnant
Where it's running
-
New Center One
Detroit, Michigan, United States Recruiting
Study contacts
- Principal investigator: Henry W Lim, MD — Henry Ford HS
- Study coordinator: Angela Parks-Miller, RN
- Email: amiller5@hfhs.org
- Phone: 1-313-916-0426
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can Gleolan help highlight kidney tumors during partial nephrectomy?
This study tests whether giving Gleolan before kidney surgery helps fluorescence identify cancer tissue in adults with suspected kidney cancer undergoing partial nephrectomy.
-
See how well ICG fluorescence can show knee tissue blood flow during arthroscopy
This study tests whether injecting a dye called ICG can help doctors see blood flow in knee tissues during arthroscopic knee surgery, including different ACL tear severities.
-
Long-acting local pain medicine after knee replacement
This study tests whether a new extended-release pain medicine (Zynrelef) given around the knee during total knee replacement can reduce pain after surgery better or as well as standard injections or nerve blocks.
-
Can blood and physical tests before transplant predict non-relapse mortality
This study tests whether pre-transplant blood markers and physical tests can predict non-relapse mortality in adults undergoing stem cell therapy.
-
Multimodal Pain Plan to Cut Opioids After Hip Replacement
This study tests whether a multimodal pain regimen with a printed opioid prescription (instead of pharmacy-direct dispensing) can control pain after hip replacement while reducing opioid use.
-
Peanut intake and liver health in adults with MASLD
This study tests whether adding peanuts to daily meals for 12 weeks can improve liver markers and metabolic health in adults with MASLD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.